Page Updated September 28, 2024

Hirva Mamdani, MD

Page Written by

Terri Heimann Oppenheimer

Page Edited by Patient Advocate

Dave Foster

Fact Checked

Dr. Hirva Mamdani is a thoracic medical oncologist who specializes in the diagnosis and treatment of patients with malignant pleural mesothelioma, esophageal cancer, lung cancer, and other thoracic malignancies.  She is the head of the Thoracic Oncology Multidisciplinary Team at Karmanos Cancer Institute in Detroit and is the Director of Lung Cancer Screening there. 

She is always mindful of the fact that “scientifically, culturally, physically, and mentally, every patient with cancer is different, so treatment has to be individualized for that particular patient.” She is glad to be able to offer patients state-of-the-art treatment and to conduct clinical research aimed at improving patient outcomes.[1]

Education and Career

Dr. Mamdani received her medical degree from M.P. Shah Medical College in India. She completed her internship and residency in Internal Medicine at Wayne State University in Detroit and her fellowship training in Hematology and Oncology at Indiana University in Indianapolis. 

She is board-certified in Internal Medicine, Medical Oncology, and Hematology. In addition to leading the Karmanos Cancer Institute’s Thoracic Oncology Multidisciplinary Team, she is also a member of its Phase I Clinical-Pharmacology Program and director of the Lung Cancer Screening Program. She is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research, and the American College of Physicians. Dr. Mamdani is a frequent presenter at professional conferences including the ASCO Gastrointestinal Cancers Symposium and the ASCO Annual Meeting.[1]

Research

Dr. Mamdani’s research interests center on the development of treatment strategies for lung cancer, and especially for overcoming cancer’s resistance to immunotherapy. She is a member of Karmanos Cancer Institute’s Phase 1 Clinical Trials Program’s multidisciplinary team and is the co-principal investigator of a study funded by the P20 Specialized Program of Research Excellence (SPORE) that is evaluating racial disparities in efficacy and toxicity of immunotherapy in patients with non-small cell lung cancer. She has received several young investigator awards and serves on the American Society of Clinical Oncology Expert Panel for developing treatment guidelines for advanced non-small cell lung cancer.  

She is actively involved in several clinical trials, including:[1]

A phase II trial of monalizumab in combination with durvalumab (MEDI4736) plus platinum-based chemotherapy for first-line treatment of extensive stage small cell lung cancer (MOZART)

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase II

A Phase II Study of GT103 in Combination with Pembrolizumab in Refractory, Metastatic Non-Small Cell Lung Cancer

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase II

A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1305 in Subjects with Advanced/Metastatic Solid Tumors

• CANCER CATEGORY
  Breast,Gastrointestinal (GI),Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

A Phase 1b/2, Single-Arm, Open-Label, Dose-Escalation, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of Chiauranib for the Treatment of Advanced Solid Malignant Tumors and Relapsed/Refractory Small Cell 

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

A Phase 1 Study to Assess the Safety and Efficacy of LYL797, ROR1-Targeting CAR T Cells, in Adults with Relapsed and/or Refractory Solid Tumor Malignancies 

• CANCER CATEGORY
  Breast,Lung
• AGE GROUP
  Adult
• PHASE
  Phase I

Phase I/II Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT5528 in Patients with Advanced Malignancies Associated with EphA2 Expression

• CANCER CATEGORY
  Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

A Phase I, Dose Escalation Safety and Tolerability Study of VAXINIA (CF33-hNIS), Administered Intratumorally or Intravenously as a Monotherapy or in Combination with Pembrolizumab in Adult Patients with Metastatic or Advanced Solid Tumors (MAST)

• CANCER CATEGORY
  Breast,Gastrointestinal (GI),Genitourinary (GU),Gynecologic,Head and Neck,Lung
• AGE GROUP
  Adult
• PHASE
  Phase I

A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 in Patients with Advanced Cancers Associated with Expression of Delta-Like Canonical Notch Ligand 3 (DLL3) Who Have Fa

• CANCER CATEGORY
  Gastrointestinal (GI),Genitourinary (GU),Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase I

A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

• CANCER CATEGORY
  Lung
• AGE GROUP
  Adult
• PHASE
  Phase I/II

Terri Heimann Oppenheimer

Writer

Terri Oppenheimer has been writing about mesothelioma and asbestos topics for over ten years. She has a degree in English from the College of William and Mary. Terri’s experience as the head writer of our Mesothelioma.net news blog gives her a wealth of knowledge which she brings to all Mesothelioma.net articles she authors.

Connect with Terri Heimann Oppenheimer

Dave Foster

Page Editor

Dave has been a mesothelioma Patient Advocate for over 10 years. He consistently attends all major national and international mesothelioma meetings. In doing so, he is able to stay on top of the latest treatments, clinical trials, and research results. He also personally meets with mesothelioma patients and their families and connects them with the best medical specialists and legal representatives available.

Connect with Dave Foster